Q-omics provides the consensus-scored CERS4 profile across patient tissues and cancer cell-line models. CERS4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CERS4 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CERS4 protein abundance shows 21,177 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, LUAD, and PDAC as cancer lineages where CERS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERS4 survival associations across molecular data types. CERS4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERS4 RNA expression–survival associations across cancer types. High CERS4 expression shows favorable associations in HNSC, CESC, LUAD, KIRP, PAAD and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CERS4 RNA expression.
This table summarizes CERS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CERS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERS4 shows lower tumor expression in LUAD, BLCA and COAD and higher tumor expression in KIRC, KICH and BRCA. The LUAD box plot shows higher CERS4 RNA expression in normal versus tumor tissue (log2 FC = −1.273, t-test p < 0.001).
This table shows molecular features associated with CERS4 in patient tissues and cancer cell lines. In patient samples, CERS4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CERS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
